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1. Introduction pletely, whereas the other 2 have a relatively small 
effect. 
Monoclonal antibodies, produced by somatic ell 
fusion [l] provide useful tools for (among other 
things) comparison of the structures of related mole- 
cules and for the study of structure-function relation- 
ships. Different monoclonal antibodies raised against 
a single protein antigen will often show specificity 
for different sites on that antigen; consequently some 
of these antibodies may interfere with biological 
activity (by blocking receptor-binding sites) whereas 
others may fail to do so (because they interact at 
some distance from the receptor-binding site). 
2. Methods 
2.1. Iodination of human growth hormone 
A series of monoclonal antibodies to human growth 
hormone (hGH), only some of which cross-react with 
the structurally related hormone human placental 
lactogen, has been described [2,3]. Each of these 
monoclonal antibodies reacts with 1 of at least 4 dif- 
ferent antigenic determinants on the hGH molecule. 
It was of interest herefore to determine whether 
these antibodies could interfere with the interaction 
between labelled hGH and receptors from rabbit liver 
or mammary gland. The mammary gland receptors 
are specific for lactogenic hormones uch as prolactin 
and human (but not non-primate) growth hormone 
[4], whereas the liver receptors bind prolactins and 
growth hormones from several different species [ 51, 
but show a species pecificity that does not accord 
well with the biological actions of the hormone [6,7]. 
These results how that 2 of the 4 monoclonal anti- 
bodies tested can block receptor binding almost com- 
hGH was a gift from the National Institute of 
Biological Standards and Control (Hampstead) and 
was labelled with Na”‘I (obtained from the Radio- 
chemical Centre, Amersham, Bucks) by the ‘iodogen’ 
method [8] as in [7]. r2’I-Labelled hormone and free 
12’1- were separated by chromatography on a column 
(0.78 cm2 X 11-14 cm) of Sephadex G-50 (Fine 
grade). *2SI-L.abelled hGH was rechromatographed 
before use on a column (0.78 cm2 X 90-95 cm) of 
Sephadex G-100 (Superfine grade) equilibrated and 
eluted with Tris-HCl buffer (0.025 M Tris adjusted 
to pH 7.6 with HCl) containing 0.1% bovine serum 
albumin and 0.6 mM merthiolate, at 4°C. 
2.2. Preparation of membrane-bound receptors 
Membrane-bound receptors were prepared as a 
microsomal fraction from liver and from mammary 
gland of late-pregnant New Zealand White rabbits, 
by differential centrifugation of a crude homogenate, 
asin [7]. 
2.3. Monoclonal an tibodies to human growth hormone 
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Antibodies from 4 hybridoma cell lines secreting 
mouse monoclonal IgG antibodies against hGH were 
used. These have been designated NA27, NA39, NA71 
and QA68 and their preparation and characterization 
has been described [2,3]. 
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2.4. Effect of antibodies on receptor binding 
When ‘2sI-labelled hGH was incubated with mem- 
brane-bound receptors from rabbit liver or mammary 
gland, a substantial proportion (2040%, at the con- 
centrations of receptors used) of the labelled hormone 
was bound specifically. The ability of antibodies to 
interfere with such binding was assessed by preincu- 
bating 12SI-labelled hormone with various concentra- 
tions of each of the 4 monoclonal antibodies. 
All dilutions of tracer, antibody and receptors 
were carried out with ‘Tris-HCl assay buffer’ (0.025 M 
Tris-HCl (pH 7.6) containing 0.1% bovine serum 
albumin, 0.6 mM merthiolate and 10 mM CaCl2). 
Antibody titration curves were set up in triplicate for 
each of the 4 monoclonal antibodies. 100 r_l1 2’1- 
Labelled hGH (-30 000 cpm) was added to 100 I_ll 
antibody (serially diluted over the appropriate range) 
and 200 /.d ‘Tris-HCl assay buffer’. Tubes were incu- 
bated at 20-25°C for 48 h or at 4°C for 72 h. 100 fl 
NA 71 QA 68 NA 39 NA 27 
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(200-300 pg protein) of receptor preparation (mem- 
brane-bound from rabbit liver or mammary gland) or 
buffer was then added and the tubes were reincubated 
overnight at 4°C. In those tubes containing antibody 
and receptor, receptor-bound tracer was precipitated 
by the addition of 3 ml ice-cold sodium acetate buffer 
(0.025 M sodium acetate (pH 5.4), containing 0.1% 
BSA). In those tubes containing antibody only, anti- 
body-bound tracer was precipitated by the addition 
of 0.5 ml poly(ethylene glycol) mixture containing 
25% (w/v) poly(ethylene glycol), 0.15% bovine r_glo- 
bulin and 0.05 M Tris-HCl (pH 8.5) [9]. In both 
cases free and bound hormone were separated by cen- 
trifugation (20 min, -1000 X g, 4”C), supernatants 
were removed by aspiration and the precipitates were 
subjected to y-counting in a Nuclear Chicago y-radia- 
tion counter (model 1195); counting efficiency for 
12’1 was 50-55%. 
60 
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ANTIBODY CONCENTRATION (rag/ ml) 
Fig.1. The effect of monoclonal antibodies on binding of ‘251-labeIled human growth hormone to membrane-bound receptors 
from rabbit mammary gland and liver. W-hGH (-30 000 cpm) was preincubated with various concentrations (based on freeze- 
dried material) of each antibody, for 48 h. Buffer (A) or liver receptors (B) or mammary gland receptors (C) were then added and 
incubation was continued for a further 24 h. Binding of ‘251-hGH to antibody (A) or receptors (B,C) was then determined as 
described in the text. Label ‘bound’ in the absence of receptor or antibody was considered ‘non-specific’. Each value is the mean 
of triplicate determinations: (-•-) (A), specific binding to antibody (% of total cpm); (-•-) (B), specific binding to liver recep- 
tors (% of maximum specific binding); (-A-) (C), specific binding to mammary gland receptors (% of maximum specific binding). 
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3. Results 
Fig.1 shows the effect of preincubation with each 
of the monoclonal antibodies on the binding of 
‘*‘I-hGH to rabbit liver and mammary gland receptors. 
In the case of NA71 an increase in the amount of 
tracer bound to antibody caused aproportional 
decrease in the amount bound to receptor, until at 
the highest concentration of antibody, receptor bind- 
ing was negligible. The concentration of antibody 
required to cause 50% inhibition of specific binding 
to receptors was close to the concentration which 
gave 50% of maximum specific binding to antibody in 
the absence of receptors. The effects of NA71 on the 
binding of ‘*‘I-hGH to both types of receptor, rabbit 
liver and mammary gland, were very similar. 
A similar esult was obtained with the antibody 
QA68, although in this case binding to the antibody 
could not entirely prevent binding of ‘*‘I-hGH to 
liver receptors. Even at the highest concentration of 
antibody, specific binding to these receptors did not 
fall below 20%. 
A very different result was obtained with the anti- 
bodies NA27 and NA39. Fig.1 (NA27) shows that an 
increase in the proportion of antibody-bound tracer 
caused only a small decrease in receptor binding, and 
this appeared to level off at 60-70% of total specific 
binding. The effect of preincubation with NA27 on 
the binding of ‘*‘I-hGH to both types of receptor was 
similar. The results obtained with the antibody NA39 
(fig.1) were almost identical to those obtained with 
NA27. Again specific binding could not be reduced 
below 70% and the effect of the antibody on binding 
of hGH to liver and to mammary gland receptors was 
Silllh. 
4. Discussion 
hGH binding sites prepared from rabbit mammary 
gland are specifically lactogenic and are very differ- 
ent from the bulk of those in rabbit liver, which bind 
both lactogenic and somatogenic hormones [6,7]. 
Distinct structural regions within the hGH molecule 
may be involved in binding to the different ypes of 
receptor, in which case a monoclonal antibody might 
be able to block binding to one type of receptor with- 
out affecting binding to the other type. In the event, 
however, the effect of antibody on receptor binding 
was almost identical for liver and for mammary gland 
receptors, in the case of each monoclonal antibody 
tested. This suggests either that one site within the 
hGH molecule is responsible for binding to both 
types of receptor, or that if 2 sites are involved they 
are so close together that they are identically affected 
by antibody binding. This accords with the finding 
[lo] that the determinants for both hepatic and 
mammary gland receptor binding are within the first 
134 residues of the amino-terminal region of hGH. 
According to their effects on receptor binding, the 
4 monoclonal antibodies could be divided into 2 
categories, i.e., those which could almost completely 
inhibit (NA71 and QA68), and those which could 
only partially inhibit (NA27 and NA39) receptor- 
binding. There are 3 possible mechanisms by which 
antibody may effect receptor binding: 
(i) The antibody could bind to the same site as the 
receptor, thus blocking receptor binding. 
(ii) The antibody could bind to a site close to that 
for the receptor, and block receptor binding by 
steric hindrance. 
(iii) A decrease in affinity of the hormone for the 
receptor could be caused by binding of the anti- 
body to a site which, although distinct from the 
receptor site, affects the conformation of the 
molecule. (A conformational effect could also 
explain the cross-reactivity in an antibody-anti- 
body competition assay between antibodies NA27 
and NA39 which bind to hGH-specific and hGH- 
human placental lactogen-shared determinants, 
respectively [3].) 
Any of these mechanisms could explain the complete 
inhibition of receptor binding obtained with antibodies 
NA71 and QA68. The partial inhibition seen with 
NA27 and NA39 could be explained by mechanisms 
(ii) or (iii), but could also be explained by heterogeneity 
of receptors; if more than one type of binding site 
was present in a receptor population it might be 
possible for the antibody to block binding to one 
type of receptor without affecting binding to a second 
type. 
An assumption made in interpreting these data is 
that binding of hormone to receptors is reversible. In 
practice this is largely the case, although complete 
dissociation of hormone-receptor complexes i  diff- 
cult [ 11 ,121. If the hormone-antibody complex could 
dissociate asily whereas binding to receptors was 
irreversible, it might be possible for receptors to 
effectively ‘strip’ labelled hormone from the hor- 
mone-antibody complex. In this case, the incomplete 
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inhibition of binding seen with antibodies NA39 and 
NA27 might be a consequence of binding of free 
(dissociated), rather than antibody-bound, hormone 
to receptors. In fact, however, dissociation of “‘I- 
hGH from antibody NA39 appears to be very slow 
(like dissociation from NA7 1) whereas dissociation 
from QA68 and (especially) NA27 is more rapid [3]; 
so if receptors could ‘strip’ 1251-hGH from antibody 
this would be most likely to happen in the cases of 
antibodies NA27 and (to a lesser extent) QA68, and 
not NA39 and NA71. 
Whatever the explanation of the results obtained, 
it is clear that the different monoclonal antibodies 
have different effects on hormone-receptor interac- 
tions, and this may eventually help to determine the 
detailed nature of such interactions. It seems likely 
from these results that the receptor-binding site must 
be larger than an antigenic determinant (epitope) 
since at least 2 monoclonal antibodies (QA68 and 
NA71) of non-overlapping combining site specificities 
[3] almost completely blocked receptor binding. 
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